AHA Scientific Sessions 2024 Late-Breaking and Featured Science Collection
Published: 29 October 2024
-
Views:
1598
-
Likes:
7
-
Views:
1598
-
Likes:
7
-
Up Next -
18m 41s -
17m 22sPart 2 | Session 3 SUMMIT: Tirzepatide in Patients with HFpEF and Obesity -
16m 57sPart 2 | Session 4 FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk -
22m 30s
-
6m 17s -
3m 53s -
7m 19sPart 3 | Session 3 Mavacamten: Real-World Experience from 22 Months of the REMS Program -
10m 31s
-
Part 4 Coming Soon
-
13m 43sPart 1 View from the Thoraxcenter: AHA 24 Late-breaking Preview Joost Daemen, Nicolas M Van Mieghem
Overview
Keep up-to-date with our video collection covering the American Heart Association's 2024 Scientific Sessions in Chicago. For expert insights on the hottest late-breaking and featured science trials, tune in to our collection.
- To catch reviews on the most awaited trials, watch our recurring series View From the ThoraxCenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
- Watch out for the Late-Breaker Discussions with Dr Harriette Van Spall for key clinical trial data and its implications for future research.
- Our concise Expert Interviews provide key data, study designs and take-home messages from select faculty.
- Don't miss the key take aways from our Highlights series.
More from this programme
Part 1
View From the Thoraxcenter
Part 2
Late-Breaker Discussions with Dr Harriette Van Spall
Part 3
Expert Interviews
Part 4
Highlights
| 1 session | |
| Coming Soon | Watch now |
About the episode
AHA Conference 2024 — Key findings from the ZODIAC trial investigating the role of a decision support system in optimising lipid-lowering therapy for ACS patients.
Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Kausik Ray (Imperial College London, UK) to discuss the findings from the randomized controlled ZODIAC trial assessing decision support systems (DSS) in optimising lipid-lowering therapies in patients with acute coronary syndrome (ACS).
The ZODIAC (NCT05844566) trial aimed to compare a DSS aligned with the 2019 ESC/EAS guidelines in addition to routine care with routine care alone in patients with ACS. The study aimed to assess whether the availability of a DSS resulted in early initiation of combination lipid-lowering therapies or the intensification of existing lipid-lowering therapy regimes over a 24-week period after an ACS event. An estimated 1,584 participants consented to randomized clinical trial sites to collect their data, where clinical sites were randomized to either standard of care or access to the DSS.
Recorded remotely from London, UK and Hamilton, CA, 2024.
Editors: Jordan Rance and Yazmin Sadik
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.
Support: This is an independent interview produced by Radcliffe Cardiology.
Faculty Biographies
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…
Kausik (Kosh) Ray
Professor of Public Health
Professor Kausik Ray is currently Professor of Public Health, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials within the Department of Public Health and Primary Care, School of Public Health, Imperial College London, Consultant Cardiologist and Chief Clinical Officer and Head of Trials – Discover Now as well as NIHR ARC National Lead of Cardiovascular Disease.
Prof Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.
A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and President-Elect of the European Atherosclerosis Society, also serving on the EAS Consensus…
Comments